CD274 and hypophysitis: On the other hand, hypophysitis associated with immunotherapy using anti-programmed death-1 (PD-1) monoclonal antibodies, such as nivolumab and pembrolizumab, or antibodies directed against programmed cell death-ligand 1 (PD-L1), such as atezolizumab and durvalumab, is much less frequent (up to 0.5%) [62].